AbbVie has struck a pivotal agreement with the U.S. administration, signaling a major evolution in healthcare policy where domestic production is now integrated into pricing negotiations.
Under the three-year pact, AbbVie will lower prices for specific Medicaid-covered drugs and utilize the TrumpRx direct-to-patient platform for distribution. In exchange, the company secures exemptions from pharmaceutical import tariffs and future price mandates. A core component of the deal is AbbVie’s commitment to invest $100 billion over the next ten years into U.S.-based R&D and capital projects, with a primary focus on domestic manufacturing.
This strategic move aligns with federal efforts to reshore pharmaceutical supply chains and reduce reliance on overseas production. AbbVie’s recent $175 million acquisition and upgrade of a facility in Arizona serves as an early blueprint for this investment cycle. The capital is expected to enhance biologics production capacity and strengthen supply-chain resilience.
This agreement adds AbbVie to a growing roster of major drugmakers—including Amgen, Novartis, GSK, and Merck—entering into “most-favored-nation” deals. These developments suggest that U.S. drug policy is shifting; beyond simple rebates, domestic manufacturing investment has become a decisive factor for companies seeking regulatory certainty and tariff relief.